CA3211113A1 - Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same - Google Patents

Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same Download PDF

Info

Publication number
CA3211113A1
CA3211113A1 CA3211113A CA3211113A CA3211113A1 CA 3211113 A1 CA3211113 A1 CA 3211113A1 CA 3211113 A CA3211113 A CA 3211113A CA 3211113 A CA3211113 A CA 3211113A CA 3211113 A1 CA3211113 A1 CA 3211113A1
Authority
CA
Canada
Prior art keywords
fibroblast
pharmaceutical composition
cell
adm
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3211113A
Other languages
English (en)
French (fr)
Inventor
Takahiro IWAMIYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metcela Inc
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of CA3211113A1 publication Critical patent/CA3211113A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3211113A 2021-03-04 2022-03-03 Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same Pending CA3211113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021-034016 2021-03-04
JP2021034018 2021-03-04
JP2021034016 2021-03-04
JP2021-034018 2021-03-04
PCT/JP2022/009205 WO2022186349A1 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
CA3211113A1 true CA3211113A1 (en) 2022-09-09

Family

ID=83155368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3211113A Pending CA3211113A1 (en) 2021-03-04 2022-03-03 Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same

Country Status (8)

Country Link
US (1) US20240148795A1 (https=)
EP (1) EP4302771A4 (https=)
JP (2) JP7233147B2 (https=)
KR (1) KR20230154177A (https=)
AU (1) AU2022231584A1 (https=)
CA (1) CA3211113A1 (https=)
IL (1) IL305069A (https=)
WO (1) WO2022186349A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
JP2025515887A (ja) 2022-11-11 2025-05-20 エルジー エナジー ソリューション リミテッド 負極活物質、これを含む負極、これを含む二次電池、および負極活物質の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
EP3845635A4 (en) 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease

Also Published As

Publication number Publication date
WO2022186349A1 (ja) 2022-09-09
JP2023058660A (ja) 2023-04-25
EP4302771A1 (en) 2024-01-10
AU2022231584A1 (en) 2023-09-07
KR20230154177A (ko) 2023-11-07
IL305069A (en) 2023-10-01
US20240148795A1 (en) 2024-05-09
JP7233147B2 (ja) 2023-03-06
EP4302771A4 (en) 2025-04-02
JPWO2022186349A1 (https=) 2022-09-09

Similar Documents

Publication Publication Date Title
Luo et al. Human bone marrow mesenchymal stem cell-derived extracellular vesicles inhibit shoulder stiffness via let-7a/Tgfbr1 axis
Chen et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair
Nakaya et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction
Keeley et al. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis
Rieder et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis
Aird et al. Adipose-derived stromal vascular fraction cells isolated from old animals exhibit reduced capacity to support the formation of microvascular networks
Yamauchi et al. Functional differentiation of RAMP2 and RAMP3 in their regulation of the vascular system
Huang et al. Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs
AU2020204541B2 (en) Epicardial-derived paracrine factors for repairing cardiac tissue
KR102883773B1 (ko) 섬유아세포의 제조 방법 및 g-csf 양성 섬유아세포 집단
US20240148795A1 (en) Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
Paddock et al. IL4Rα signaling promotes neonatal cardiac regeneration and cardiomyocyte cell cycle activity
Hamada et al. Xenogeneic transplantation of human adipose-derived stem cell sheets accelerate angiogenesis and the healing of skin wounds in a Zucker Diabetic Fatty rat model of obese diabetes
JP2017530977A (ja) 肺高血圧症の治療剤としての心筋球由来細胞（ｃｄｃ）
Song et al. Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway
Imhof et al. Olfactomedin‐like 3 promotes PDGF‐dependent pericyte proliferation and migration during embryonic blood vessel formation
Zhang et al. Sema4D–plexin-B1 signaling in recruiting dental stem cells for vascular stabilization on a microfluidic platform
Zou et al. Activation of bone marrow–derived cells and resident Aortic cells during aortic injury
JP2017538411A5 (https=)
Guo et al. Young human PRP promotes the rejuvenation of aged bone marrow mesenchymal stem cells and the therapeutic effect on ischemic heart disease
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
Suzuki et al. The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment
CN120114578B (zh) Senp5在制备治疗血管损伤后内膜增生药物中的应用
US20250388868A1 (en) Leveraging type 2 cytokines to enhance cell-based therapy for peripheral arterial diseases
EP3593816A1 (en) Lypd1 inhibitor and method for producing biological tissue using same

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241009

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250512

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250517

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260414